ZATA Pharmaceuticals, Inc.
ZATA’s founders have been leaders in the advancement of DNA/RNA-based technologies. Their experience, vision, and continuing contribution to synthetic DNA/RNA-based drug discovery and development make ZATA a promising new leader in the field.
ZATA Pharmaceuticals, Inc. was founded in 2008 by Dr. David Tabatadze and Dr.Paul Zamecnik. Dr. Tabatadze has MS in an organic chemistry and a Ph.D. in biochemistry. He has been associated for fifteen years with Dr. Zamecnik, and they have co-authored numerous publications and patents. Dr. Tabatadze’s expertise includes conception of potential therapeutic compounds, synthesis and scale-up of biologically active molecules, drug metabolism of human blood products, biochemical, biophysical and bioanalytical evaluation of potential therapeutic compounds. Dr. Zamecnik pioneered the in vitro synthesis of proteins, he was the co-discoverer of tRNA and is known as "the father of Antisense Chemistry”. Dr. Zamecnik received the Albert Lasker Lifetime Science Award, the Presidential Medal of Science, numerous other awards and honorary degrees. Dr. Zamecnik suddenly passed away and was buried on cemetery of Harvard University in November 2009.
Our Business
A strong Intellectual property portfolio makes ZATA promising startup pharmaceutical company. On top of that founders of the company have strong expertise in the fields of pharmaceutical industry involving nucleic acid derivatives as potential therapeutic compounds. Expertise in science behind the synthesis and testing of chemically modified oligo-RNA/DNA as potential therapeutics, personal associated with ZATA also have great relationships to leading scientists and companies around the globe in the field of nucleic acid chemistry.
